These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29075107)

  • 1. A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD.
    Cantor J; Ma S; Turino G
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2747-2752. PubMed ID: 29075107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy.
    Cantor JO; Ma S; Liu X; Campos MA; Strange C; Stocks JM; Devine MS; El Bayadi SG; Lipchik RJ; Sandhaus RA; Turino GM
    Respir Med; 2021 Jun; 182():106402. PubMed ID: 33906126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease.
    Turino GM; Ma S; Lin YY; Cantor JO; Luisetti M
    Am J Respir Crit Care Med; 2011 Sep; 184(6):637-41. PubMed ID: 21757624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot Randomized Controlled Trial Evaluating the Effect of Hypertonic Saline With and Without Hyaluronic Acid in Reducing Inflammation in Cystic Fibrosis.
    Brivio A; Conese M; Gambazza S; Biffi A; Tirelli AS; Russo M; Foà M; Colombo C
    J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):482-489. PubMed ID: 27149365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation.
    Ma S; Turino GM; Lin YY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(21):1893-8. PubMed ID: 21621489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy?
    Cantor JO; Cerreta JM; Ochoa M; Ma S; Liu M; Turino GM
    Lung; 2011 Feb; 189(1):51-6. PubMed ID: 21153833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Therapeutic Potential of Hyaluronan in COPD.
    Turino GM; Ma S; Lin YY; Cantor JO
    Chest; 2018 Apr; 153(4):792-798. PubMed ID: 29289686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions.
    Luisetti M; Ma S; Iadarola P; Stone PJ; Viglio S; Casado B; Lin YY; Snider GL; Turino GM
    Eur Respir J; 2008 Nov; 32(5):1146-57. PubMed ID: 18978133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of secondhand smoke exposure on markers of elastin degradation.
    Slowik N; Ma S; He J; Lin YY; Soldin OP; Robbins RA; Turino GM
    Chest; 2011 Oct; 140(4):946-953. PubMed ID: 21415130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurements of desmosine and isodesmosine by mass spectrometry in COPD.
    Ma S; Lin YY; Turino GM
    Chest; 2007 May; 131(5):1363-71. PubMed ID: 17494786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease.
    Huang JT; Chaudhuri R; Albarbarawi O; Barton A; Grierson C; Rauchhaus P; Weir CJ; Messow M; Stevens N; McSharry C; Feuerstein G; Mukhopadhyay S; Brady J; Palmer CN; Miller D; Thomson NC
    Thorax; 2012 Jun; 67(6):502-8. PubMed ID: 22250098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
    Dahl R; Titlestad I; Lindqvist A; Wielders P; Wray H; Wang M; Samuelsson V; Mo J; Holt A
    Pulm Pharmacol Ther; 2012 Apr; 25(2):169-77. PubMed ID: 22306193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable deuterium internal standard for the isotope-dilution LC-MS/MS analysis of elastin degradation.
    Ma S; Turino GM; Hayashi T; Yanuma H; Usuki T; Lin YY
    Anal Biochem; 2013 Sep; 440(2):158-65. PubMed ID: 23727558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis.
    de Brouwer B; Drent M; van den Ouweland JMW; Wijnen PA; van Moorsel CHM; Bekers O; Grutters JC; White ES; Janssen R
    Respir Res; 2018 Mar; 19(1):45. PubMed ID: 29558926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antritrypsin deficiency-related COPD.
    Fregonese L; Ferrari F; Fumagalli M; Luisetti M; Stolk J; Iadarola P
    COPD; 2011 Oct; 8(5):329-33. PubMed ID: 21793711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients.
    Viglio S; Iadarola P; Lupi A; Trisolini R; Tinelli C; Balbi B; Grassi V; Worlitzsch D; Döring G; Meloni F; Meyer KC; Dowson L; Hill SL; Stockley RA; Luisetti M
    Eur Respir J; 2000 Jun; 15(6):1039-45. PubMed ID: 10885422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.